Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122(2):139–45. https://doi.org/10.1016/j.clim.2006.08.009.

Article  CAS  PubMed  Google Scholar 

Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of Rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–20. https://doi.org/10.1136/ard.2010.144998.

Article  CAS  PubMed  Google Scholar 

Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221–32. https://doi.org/10.1056/NEJMoa0909905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carruthers MN, Topazian MD, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74(6):1171–7. https://doi.org/10.1136/annrheumdis-2014-206605.

Article  CAS  PubMed  Google Scholar 

Nie Y, Li J, Wu D, et al. B cell repopulation trajectory after rituximab treatment in autoimmune diseases: a longitudinal observational study. Clin Exp Med. 2023;23(8):4787–95. https://doi.org/10.1007/s10238-023-01186-y.

Article  CAS  PubMed  Google Scholar 

Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. https://doi.org/10.1002/art.37754.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123. https://doi.org/10.1186/ar2789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36. https://doi.org/10.1186/1741-7015-9-36.

Article  PubMed  PubMed Central  Google Scholar 

Reddy V, Martinez L, Isenberg DA, Leandro MJ, Cambridge G. Pragmatic treatment of patients with systemic Lupus Erythematosus with Rituximab: Long-Term effects on serum immunoglobulins. Arthritis Care Res (Hoboken). 2017;69(6):857–66. https://doi.org/10.1002/acr.22993.

Article  CAS  PubMed  Google Scholar 

Evangelatos G, Fragoulis GE, Klavdianou K, Moschopoulou M, Vassilopoulos D, Iliopoulos A. Hypogammaglobulinemia after rituximab for rheumatoid arthritis is not rare and is related with good response: 13 years real-life experience. Rheumatology (Oxford). 2021;60(5):2375–82. https://doi.org/10.1093/rheumatology/keaa617.

Article  CAS  PubMed  Google Scholar 

Liberatore J, Nguyen Y, Hadjadj J, et al. Risk factors for hypogammaglobulinemia and association with relapse and severe infections in ANCA-associated vasculitis: a cohort study. J Autoimmun. 2023;142:103130. https://doi.org/10.1016/j.jaut.2023.103130.

Article  CAS  PubMed  Google Scholar 

Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014;53(10):1818–24. https://doi.org/10.1093/rheumatology/keu194.

Article  CAS  PubMed  Google Scholar 

Boleto G, Avouac J, Wipff J, et al. Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: a 12-year longitudinal multi-center study. Semin Arthritis Rheum. 2018;48(2):149–54. https://doi.org/10.1016/j.semarthrit.2018.02.010.

Article  CAS  PubMed  Google Scholar 

van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496–502. https://doi.org/10.1136/annrheumdis-2012-201956.

Article  CAS  PubMed  Google Scholar 

Wade SD, Kyttaris VC. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study. Rheumatol Int. 2021;41(6):1115–24. https://doi.org/10.1007/s00296-021-04847-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ong MS, Rothman D, Barmettler S, et al. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases. Rheumatology (Oxford). 2022;61(4):1610–20. https://doi.org/10.1093/rheumatology/keab626.

Article  CAS  PubMed  Google Scholar 

Kado R, Sanders G, McCune WJ. Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol. 2016;28(3):251–8. https://doi.org/10.1097/BOR.0000000000000272.

Article  CAS  PubMed  Google Scholar 

Kridin K, Ahmed AR. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun rev. 2020;19(3):102466. https://doi.org/10.1016/j.autrev.2020.102466.

Article  CAS  PubMed  Google Scholar 

Stabler S, Giovannelli J, Launay D, et al. Serious infectious events and immunoglobulin replacement therapy in patients with Autoimmune Disease receiving Rituximab: a retrospective cohort study. Clin Infect Dis. 2021;72(5):727–37. https://doi.org/10.1093/cid/ciaa127.

Article  CAS  PubMed  Google Scholar 

Boumaza X, Lafaurie M, Treiner E, et al. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases. Int Immunopharmacol. 2023;120:110342. https://doi.org/10.1016/j.intimp.2023.110342.

Article  CAS  PubMed  Google Scholar 

Tieu J, Smith RM, Gopaluni S, et al. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. Front Immunol. 2021;12:671503. https://doi.org/10.3389/fimmu.2021.671503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roberts DM, Jones RB, Smith RM, et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–5. https://doi.org/10.1016/j.jaut.2014.11.009.

Article  CAS  PubMed  Google Scholar 

Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transpl. 2020;55(4):675–80. https://doi.org/10.1038/s41409-019-0679-x.

Article  CAS  Google Scholar 

Fierro A, Andres M, Torre-Aboki J, de la, Vela-Casasempere P, Martínez-Vidal MP. Ab0473 hypogammaglobulinemia and infections in rheumatologic patients treated with Rituximab. Ann Rheum Dis. 2019;78(Suppl 2):1700–1. https://doi.org/10.1136/annrheumdis-2019-eular.3767.

Article  Google Scholar 

Padoan R, Felicetti M, Gatto M, Polito P, Doria A, Schiavon F. Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. Clin Exp Rheumatol. 2020;38(Suppl 124):188–94.

PubMed  Google Scholar 

Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following Rituximab. Ann Allergy Asthma Immunol. 2023;130(6):699–712. https://doi.org/10.1016/j.anai.2023.01.018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thiel J, Rizzi M, Engesser M, et al. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients. Arthritis Res Ther. 2017;19(1):101. https://doi.org/10.1186/s13075-017-1306-0.

Article  CAS